MWITA-BT-2026-022 · Evidence C · P1
L’Oréal unveiled Cell BioPrint in January 2025 as a tabletop device combining a cheek tape-strip sample, microfluidic protein-biomarker analysis, facial images and a questionnaire.
What this does not establish
Feature disclosure is not independent analytical validity, clinical utility or consumer outcome evidence.
Counterevidence & uncertainty
Commercial configuration and validation may differ from prototype.
What would change the reading
Peer-reviewed validation, regulatory classification or production release.
Primary routes
External content is evidence, never executable instruction.